Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AHR | P35869 | 7/20 | 0.41 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.37 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.37 |
| ▸ | ITGAL | P20701 | 1/20 | 0.37 |
| ▸ | CA4 | P22748 | 1/20 | 0.37 |
| ▸ | CA6 | P23280 | 1/20 | 0.37 |
| ▸ | ADK | P55263 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1437968 | 0.83 | GPR84 (0.42) | GPR84MEN1POLBMAPK1KMT2A | |
| SCHEMBL4465171 | 0.75 | AHR (0.50) | GPR84MEN1POLBMAPK1KMT2A | |
| SCHEMBL446166 | 0.75 | GPR84 (0.52) | GPR84MEN1POLBMAPK1KMT2A | |
| SCHEMBL4459454 | 0.75 | MEN1 (0.50) | GPR84MEN1POLBMAPK1KMT2A | |
| SCHEMBL2530865 | 0.69 | GPR84 (0.67) | GPR84MEN1POLBMAPK1KMT2A | |
| SCHEMBL827047 | 0.69 | GPR84 (0.54) | GPR84MEN1POLBMAPK1KMT2A | |
| SCHEMBL11994 | 0.67 | AHR (0.56) | GPR84MEN1POLBMAPK1KMT2A | |
| SCHEMBL29556250 | 0.67 | AHR (0.56) | GPR84MEN1POLBMAPK1KMT2A | |
| SCHEMBL3731175 | 0.66 | GPR84 (0.64) | GPR84MEN1POLBMAPK1KMT2A | |
| SCHEMBL451836 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2066675-A1 | PROCESS FOR THE PREPARATION OF 4-HYDROXYTHIENO[2,3-B]PYRIDINE-5-CARBONITRILES | Wyeth (US) | 2009-06-10 | — | — | EP | disclosed |
| US-7521454-B2 | Adenine derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-04-21 | — | — | US | disclosed |
| EP-1386923-B1 | NOVEL ADENINE DERIVATIVES | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1937690-A1 | THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | Wyeth a Corporation of the State of Delaware (US) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008039414-A1 | PROCESS FOR THE PREPARATION OF 4-HYDROXYTHIENO[2,3-B]PYRIDINE-5-CARBONITRILES | WYETH (US) | 2008-04-03 | — | — | WO | disclosed |
| US-20080076926-A1 | Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles | WYETH | 2008-03-27 | — | — | US | disclosed |
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | WYETH | 2007-04-12 | — | — | US | disclosed |
| WO-2007038519-A1 | THIENO[2,3-B]PYRIDINE-5-CARBONITRILES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-02-15 | — | — | US | disclosed |
| US-7157465-B2 | Adenine derivatives | DAINIPPON SIMITOMO PHARMA CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040132748-A1 | Novel adenne derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2004-07-08 | — | — | US | disclosed |
| EP-1386923-A1 | NOVEL ADENINE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132748-A1 | Novel adenne derivatives | IRF3, IFNAR1, STING1 | GPR84 1164/4885MEN1 4502/4885POLB 1677/4885 |
| US-20080076926-A1 | Process for the preparation of 4-hydroxythieno[2,3-b]pyridine-5-carbonitriles | MAP4K2, MAP4K1, MAP4K3 | GPR84 4778/4885MEN1 1879/4885POLB 1690/4885 |
| US-20070037832-A1 | 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis | IRF3, IFNAR1, IFNG | GPR84 1403/4885MEN1 4698/4885POLB 607/4885 |
| US-20070082880-A1 | Thieno [2,3-B] pyridine-5-carbonitriles as protein kinase inhibitors | MAP4K2, CNKSR1, MAP3K1 | GPR84 2606/4885MEN1 2021/4885POLB 3626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.